SecBot SecBot

TRVI

Trevi Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001563880 Biotech & Drug Discovery
$13.29 −0.36 (−2.64%)
Nov 16 4:00 PM ET · prev $13.65
Market cap
$1.9B
Small cap
Median target
$25.00
+88% · range $23.00–40.00
1 year
+17.1%
from $11.35 · Nov 17
30 days
+11.7%
from $11.90
52-week range
$9.99–19.50
−32% from high · low Jan 23
Avg volume 20D
1.62M
shares / day
Short interest
16.86M
≈11.8% of shares · +5.3%
Days to cover
10.1
at average volume
Insider net
−$594.2K
0 buyers · 1 seller · 12 mo
New fund stakes
1
Q3 2026 13F · 1 exit
Filing reports
7
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $594.2K.

  • InstitutionsBULLISH

    Q3 2026: 23 added (1 new), 15 trimmed or exited. Largest new: Federated Hermes, $11.1M.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.129 → −$0.133 over 90 days. 1 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +5.3% to 16.86M shares. 10.1 days to cover, ≈11.8% of shares.

  • TrendRANGE

    5% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
1
exit
$11.1M
in new stakes
FundMoveSharesValue
Assenagon Asset Management S.A.DOUBLED3,527,035$50.5M
Candriam S.C.A.ADD1,308,104$18.8M
FRANKLIN TEMPLETON INCDOUBLED1,043,859$14.6M
Qube Research & Technologies LtdDOUBLED880,401$12.6M
FEDERATED HERMES, INC.NEW773,744$11.1M
Bank of New York Mellon CorpDOUBLED686,568$9.8M
CITIGROUP INCDOUBLED488,496$7.0M
UBS Group AGADD410,067$5.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2026
12-month targets · 11 analysts

Price is below the lowest target. Median implies +88%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Aug 14, 2026Jones Trading
MAINTAIN
MAINTAINBuy
Aug 7, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Aug 7, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
Jul 21, 2026BMO Capital
INITIATE
INITIATEOutperform
Jul 20, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy
Jul 20, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$594.2K
sold · 1 insider
DateInsiderTypeValue
Sep 15, 2026
Heffernan Michael Thomas
Director
Sep 15, 2026
EXERCISE$56.0K
Sep 15, 2026
Heffernan Michael Thomas
Director
Sep 15, 2026
SELL$276.5K
Sep 15, 2026
Heffernan Michael Thomas
Director
Sep 15, 2026
SELL$1.6K
Sep 15, 2026
Heffernan Michael Thomas
Director
Sep 15, 2026
EXERCISE$70.1K
Sep 15, 2026
Heffernan Michael Thomas
Director
Sep 15, 2026
SELL$316.2K
Jun 3, 2026
Heffernan Michael Thomas
Director
Jun 3, 2026
AWARD35,000 sh
Jun 3, 2026
Colangelo Dominick
Director
Jun 3, 2026
AWARD35,000 sh
Jun 3, 2026
Meeker David P
Director
Jun 3, 2026
AWARD35,000 sh

Earnings setup

Estimates
−$0.13
EPS estimate, this quarter
−3%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.18–-$0.11+0.0%$0.00
Next Q-$0.16-$0.17–-$0.12+0.0%$0.00
Current FY-$0.50-$0.55–-$0.47-4.9%$0.00
Next FY-$0.60-$0.81–-$0.39-3.8%$0.00

Short side

FINRA· Oct 30, 2026
16,855,987
shares short
+5.3%
vs prior settlement
10.1
days to cover
≈11.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 9, 2026 SEC
Trevi Therapeutics reported a Q3 2026 net loss of $21.5 million, wider than the $11.8 million loss in Q3 2025, driven…
8-K · Impact 4/10
Nov 9, 2026 Earnings result
TRVI Q3 2026 Earnings: EPS $-0.13 (+5.4% vs est)
Oct 27, 2026 SEC
BlackRock, Inc. filed an amendment to its Schedule 13G for Trevi Therapeutics, Inc., reporting beneficial ownership of…
SC 13G/A · Impact 2/10
Sep 30, 2026 Inst.
Assenagon Asset Management S.A. · DOUBLED
3,527,035 shares ($50.5M)
Sep 30, 2026 Inst.
Candriam S.C.A. · ADD
1,308,104 shares ($18.8M)
Sep 15, 2026 Insider
Heffernan Michael Thomas acquired via exercise 18,421 shares
Director @ $3.04 ($56.0K)
Sep 15, 2026 Insider
Heffernan Michael Thomas sold 18,321 shares
Director @ $15.09 ($276.5K)
Sep 15, 2026 Insider
Heffernan Michael Thomas sold 100 shares
Director @ $15.88 ($1.6K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 9, 2026
Earnings result
TRVI Q3 2026 Earnings: EPS $-0.13 (+5.4% vs est)
Oct 30, 2026
Short interest
Short Interest: TRVI up 5% to 16.9M shares
Settlement 2026-10-30 | Days to cover: 10.13 | ≈11.83% of shares outstanding (est.)
Oct 27, 2026
Press release
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET Fireside chat with management on Wednesday, November 11, 2026, at…
Sep 30, 2026
Short interest
Short Interest: TRVI up 21% to 14.6M shares
Settlement 2026-09-30 | Days to cover: 8.33 | ≈10.27% of shares outstanding (est.)
Sep 3, 2026
Press release
Trevi Therapeutics to Participate in Upcoming September Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing…

SecBot reports

7 filings · 5 press releases · 0 bullish · 2 bearish · 2 mixed · 3 neutral
All TRVI filing & press-release reports (12)